

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|----------------|----------------------|-------------------------|------------------|
| 09/462,480 | 03/06/2000 | BRIGITTE GICQUEL | 0660-0165-0X | 5139 |
| 7 | 590 04/03/2002 | | | |
| OBLON SPIV | VAK MCCLELLAND | | EXAMINER | |
| MAIER & NEUSTADT 1755 JEFFERSON DAVIS HIGHWAY FOURTH FLOOR | | | SWARTZ, RODNEY P | |
| | | | | |
| ARLINGTON, VA 22202 | | ŧ | ART UNIT | PAPER NUMBER |
| Ź | | | 1645 | • |
| | | | DATE MAILED: 04/03/2002 | (8 |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) | | | | |
|---|---|--|--|--|--|--|
| 1 | 09/462,480 | GICQUEL ET AL. | | | | |
| Office Action Summary | Examiner | Art Unit | | | | |
| | Rodney P. Swartz, Ph.D. | 1645 | | | | |
| The MAILING DATE of this communication app Period for Reply | ears on the cover sheet with the c | orrespondence address | | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing | 86(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE | nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133). | | | | |
| earned patent term adjustment. See 37 CFR 1.704(b). Status | | | | | | |
| 1) Responsive to communication(s) filed on | · | | | | | |
| 2a)⊠ This action is FINAL . 2b)□ Thi | s action is non-final. | | | | | |
| 3) Since this application is in condition for allowa closed in accordance with the practice under the practice of Claims. | | | | | | |
| Disposition of Claims 4) M. Claim(a), 55, 70 in/org panding in the application | _ | | | | | |
| 4) ☐ Claim(s) <u>56-70</u> is/are pending in the applicatio 4a) Of the above claim(s) is/are withdraw | | | | | | |
| 5) Claim(s) is/are allowed. | with troth consideration. | | | | | |
| | | | | | | |
| 6)⊠ Claim(s) <u>56-70</u> is/are rejected. 7)□ Claim(s) is/are objected to. | | | | | | |
| 8) Claim(s) are subject to restriction and/or | election requirement | | | | | |
| Application Papers | ciccion requirement. | | | | | |
| 9) The specification is objected to by the Examiner | •, | | | | | |
| 10) The drawing(s) filed on is/are: a) □ accep | ted or b)□ objected to by the Exa | miner. | | | | |
| Applicant may not request that any objection to the | e drawing(s) be held in abeyance. So | ee 37 CFR 1.85(a). | | | | |
| 11)☐ The proposed drawing correction filed on | is: a) approved b) disappro | ved by the Examiner. | | | | |
| If approved, corrected drawings are required in reply to this Office action. | | | | | | |
| 12) The oath or declaration is objected to by the Exa | aminer. | | | | | |
| Priority under 35 U.S.C. §§ 119 and 120 | | | | | | |
| 13) Acknowledgment is made of a claim for foreign | priority under 35 U.S.C. § 119(a |)-(d) or (f). | | | | |
| a) ☐ All b) ☐ Some * c) ☐ None of: | | | | | | |
| 1. Certified copies of the priority documents | s have been received. | | | | | |
| 2. Certified copies of the priority documents | s have been received in Application | on No | | | | |
| 3. Copies of the certified copies of the prior application from the International Bur* See the attached detailed Office action for a list of the certified copies of the prior application. | eau (PCT Rule 17.2(a)). | - | | | | |
| 14) Acknowledgment is made of a claim for domestic | priority under 35 U.S.C. § 119(e | e) (to a provisional application). | | | | |
| a) The translation of the foreign language pro | • • | | | | | |
| Attachment(s) | | | | | | |
| 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) | 5) Notice of Informal F | (PTO-413) Paper No(s) Patent Application (PTO-152) | | | | |
| | | | | | | |

U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Application/Control Number: 09/462,480 Page 2

Art Unit: 1645

DETAILED ACTION

1. Applicants' Response to Office Action, received 11January2002, paper#16, is acknowledged.

Claims 1-55 have been canceled with prejudice.

1

New claim 56-70 have been added. However, it is noted that two identical claim 60 appear in applicants' response, i.e., once at the bottom of page 5 and again at the top of page 6. Therefore, the duplicate claim 60 at the top of page 6 has not been entered.

2. Claims 56-70 are pending and under consideration.

Drawings

3. The formal drawings received 11January2002, paper#17, have been reviewed by the Draftsperson and approved.

Rejection Withdrawn

- 4. The rejection of claims 16-24, 26-29, 31, and 33 under 35 U.S.C. §112, second paragraph, indefiniteness for dependence from a nonelected claim, is most in light of the cancelation of the claims.
- 5. The rejection of claims 21 and 22 under 35 U.S.C. §112, second paragraph, lack of antecedent basis, is most in light of the cancelation of the claims.
- 6. The rejection of claims 21 and 22 under 35 U.S.C. §112, second paragraph, indefiniteness for "portions of the polypeptide of SEQ ID NO:4", is most in light of the cancelation of the claims.

Application/Control Number: 09/462,480

Art Unit: 1645

ه. مسد

- 7. The rejection of claim 23 under 35 U.S.C. §112, second paragraph, indefiniteness for "MAP" and "under the form of", is most in light of the cancelation of the claim.
- 8. The rejection of claim 23 under 35 U.S.C. §112, second paragraph, indefiniteness for "additional T-epitope", is most in light of the cancelation of the claim.
- 9. The rejection of claims 23, 24, 26-29, 31, and 33 under 35 U.S.C. §112, second paragraph, indefiniteness for lack of antecedent basis, is most in light of the cancelation of the claims.
- 10. The rejection of claims 27-29 under 35 U.S.C. §112, first paragraph, scope of enablement for "vaccines", is most in light of the cancelation of the claims.
- 11. The rejection of claim 31 under 35 U.S.C. §112, second paragraph, incomplete for omitting essential steps, is most in light of the cancelation of the claim.
- 12. The rejection of claim 31 under 35 U.S.C. §112, second paragraph, indefiniteness for detection of whole bacterium, is most in light of the cancelation of the claim.

Rejections Maintained

13. The rejection of claims prior 16, 23, 24, 26-29, 31 and 33, now rewritten as new claims 56-70 under 35 U.S.C. §112, second paragraph, indefiniteness for polypeptide expressed by a host "containing" specific polynucleotides, is maintained.

The newly rewritten claims, dependent from claims 56 and 57, remain drawn to a purified polypeptide expressed by a recombinant host which contains a polynucleotide selected from

•

400

polynucleotides "comprising" various specific polynucleotides. The open language of the new claims does not correct indefiniteness of the prior rejected claims.

Claim 57 is drawn to a purified polypeptide comprising at least one antigenic portion of a polypeptide comprising SEQ ID NO:5 or specific portions of SEQ ID NO:5. However, because of the open language "comprising", the antigenic portion is not restricted to SEQ ID NO:5 but may also originate in the nondefined regions of the polypeptide.

14. The rejection of claims prior 31 and 33, now rewritten as new claims 69 and 70 under 35 U.S.C. §112, first paragraph, scope of enablement, for antibody assays or other proteins is maintained for reasons of record.

The newly rewritten claims remain drawn to a method and kit comprising a polypeptide of claim 56 (see maintained rejection immediately above). The identity of said polypeptide is not restricted to the specific SEQ ID Nos nor even to *Mycobacterial* origin. In addition, the specification to which applicants' response is directed teaches only DTH responses, not antibody responses.

Conclusion

- 15. No claims are allowed.
- 16. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

Art Unit: 1645

MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

17. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rodney P. Swartz, Ph.D., whose telephone number is (703) 308-4244. The examiner can normally be reached on Monday through Thursday from 5:30 AM to 4:00 PM EST.

If attempts to reach the Examiner by telephone are unsuccessful, the examiner's supervisor, Lynette F. Smith, can be reached on (703)308-3909. The facsimile telephone number for the Art Unit Group is (703)308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703)308-0196.

ODNEY P SWARTZ, PH.D PRIMARY EXAMINER Art Unit 1645

April 1, 2002